Reckitt Benckiser Group plc (OTCMKTS:RBGLY) Given Consensus Rating of “Hold” by Analysts

Reckitt Benckiser Group plc (OTCMKTS:RBGLY) has earned a consensus rating of “Hold” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $5,400.00.

Several research analysts have commented on the company. JPMorgan Chase & Co. downgraded Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a report on Thursday, August 29th. UBS Group upgraded Reckitt Benckiser Group to a “strong-buy” rating in a report on Wednesday, September 18th.

Reckitt Benckiser Group Stock Up 1.3 %

Shares of RBGLY opened at $12.64 on Monday. Reckitt Benckiser Group has a 12-month low of $10.24 and a 12-month high of $15.03. The business has a 50-day simple moving average of $11.49 and a two-hundred day simple moving average of $11.29.

Reckitt Benckiser Group Cuts Dividend

The firm also recently announced a dividend, which was paid on Monday, September 23rd. Investors of record on Monday, August 5th were issued a $0.1915 dividend. The ex-dividend date was Monday, August 5th.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.